Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 21 recruiting now early-phase tilt

Malignant Neoplasm: early-phase trial registry

21 of 61 indexed Malignant Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #232 of 28,707 conditions by registered trial count.

61 US clinical trials · 21 currently recruiting · #232 of 28,707 conditions by registered trial count

Malignant Neoplasm: 61 US clinical trials tracked, 21 recruiting.

Malignant Neoplasm is the subject of 61 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 14 of these trials.

Enrollment posture brief

Registry condition malignant-neoplasm

OPEN 21 | RECR 34% | LATE 4 | EARLY 18 | RANK #232 | SPON 14

Nearest open-share peer: Chronic Lymphocytic Leukemia (34% recruiting · 189 trials)

Cholangiocarcinoma59%Cognitive Decline58.1%Depressive Symptoms45.9%Malignant Neoplasm (this)34%HIV/AIDS24.2%
Open-enrollment share among volume-matched conditions near Malignant Neoplasm

Malignant Neoplasm lists 21 open slots (34% of 61 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Malignant Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Malignant Neoplasm is recruiting below its size-band peers.

    21 of 61 indexed trials (34.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Malignant Neoplasm research.

    M.D. Anderson Cancer Center accounts for 14 of 61 trials (23%). 27 distinct sponsors appear on at least one study for this condition label.

  3. Typical Malignant Neoplasm enrolment sits around 118 participants.

    Median target enrolment is 118 among the 60 trials that report a genuine target (sentinel values excluded). 25 of those (41.7%) plan for fewer than 100 participants.

  4. Malignant Neoplasm research is mostly interventional.

    48 interventional and 13 observational studies make up this index (78.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 110Phase 28Phase 34

Open and recent trials

61 total, page 2 of 2

COMPLETED Phase 2 53 participants

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

M.D. Anderson Cancer Center

NCT03040726

COMPLETED NA 41 participants

Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer

M.D. Anderson Cancer Center

NCT03445572

COMPLETED NA 30 participants

Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment

Rutgers, The State University of New Jersey

NCT03228147

COMPLETED NA 22 participants

Psycho-Educational Program in Increasing Knowledge and Satisfaction and Decreasing Distress in Younger Patients With Cancer Receiving Treatment

City of Hope Medical Center

NCT01817335

COMPLETED NA 20 participants

A Computer-Based System for Symptom Reporting in Patients With Cancer Undergoing Treatment

Thomas Jefferson University

NCT03979846

COMPLETED NA 16 participants

Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain

M.D. Anderson Cancer Center

NCT04239976

COMPLETED Phase 1 15 participants

Extended Use of Sodium Bicarbonate in Patients With Cancer

University of Arizona

NCT02531919

COMPLETED NA 14 participants

Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy

Wake Forest University Health Sciences

NCT01941810

COMPLETED NA 12 participants

Short-Term Fasting Before Chemotherapy in Treating Patients With Cancer

Mayo Clinic

NCT01175837

COMPLETED NA 12 participants

SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

University of Washington

NCT01982123

COMPLETED Phase 1 9 participants

Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer

Mayo Clinic

NCT02598726

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 8
Phase 3 4

Named interventions

Most-linked intervention names on Malignant Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
19 trials
Quality-of-Life Assessment Other
10 trials
Laboratory Biomarker Analysis Other
8 trials
questionnaire administration Other
6 trials
Best Practice Other
4 trials
Interview Other
3 trials
laboratory biomarker analysis Other
3 trials
Cetuximab Biological
3 trials

US sites by state

Facility locations filed on Malignant Neoplasm trials. A trial with sites in several states counts in each.

Texas 20 trials
California 15 trials
Illinois 11 trials
North Carolina 8 trials
Florida 8 trials
New Jersey 7 trials
Minnesota 7 trials
Pennsylvania 6 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Malignant Neoplasm page

61 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Neoplasm condition card totals 61 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.